Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma
Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization .
Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization
DRUG: Apatinib|RADIATION: TACE
Time To Progression, Time to progression is defined as stable with treatment of apatinib combined with TACE after enrollment until lesions are defined as disease progression., From the date of first procedure of apatinib combined with TACE until the time when the disease progresses, assessed up to 14 months
Overall Survival, From the date of randomization until the date of death from any cause, From the date of randomization until the date of death from any cause, assessed up to 14 months
Aptinib combined with TACE can be generated through embolization and angiogenesis by the dual target of vascular suppression.Efficacy and safety of apatinib combined with TACE in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization.